Table 1.
Patient demographic and clinical characteristics
| Number of patients, n | 27 |
|---|---|
| Male sex, n (%) | 18 (67) |
| Age (years) | 63.9 ± 10.4 |
| BMI (kg/m2) | 28.8 ± 4.3 |
| Tumor stage, n (%) | |
| IA | 0 |
| IB | 7 (26) |
| IIA | 5 (18) |
| IIB | 14 (52) |
| III | 1 (4) |
| IV | 0 |
| Tumor Location, n (%) | |
| Head | 18 (67) |
| Body | 3 (11) |
| Tail | 6 (22) |
| Preoperative biliary stent, n (%) | |
| No Stent | 11 (41) |
| Stent | 16 (59) |
| Stent type, n (%) | |
| Plastic | 7 (26) |
| Metal | 7 (26) |
| Unknown | 2 (7) |
| Neoadjuvant chemotherapy, n (%) | |
| None | 17 (63) |
| Gemcitabine | 7 (26) |
| Gemcitabine/Paclitaxel | 2 (7) |
| Gemcitabine/Oxaliplatin | 1 (4) |
| Recent antibiotic exposure (< 6 weeks preoperatively) | |
| Yes | 3 (11) |
| No | 24 (89) |
| Operative procedure, n (%) | |
| Pancreaticoduodenectomy (Whipple) | 18 (67) |
| Distal pancreatectomy and splenectomy | 9 (33) |
| Perioperative antibiotic prophylaxis, n (%) | |
| Cefazolin | 12 (44) |
| Cefoxitin | 7 (26) |
| Cefotetan | 5 (18) |
| Clindamycin | 1 (4) |
| Levofloxacin | 1 (4) |
| Unknown | 1 (4) |
| Infectious postoperative complications, n (%) | |
| None | 19 (70) |
| Superficial SSI | 3 (11) |
| Deep/organ-space SSI | 2 (7) |
| Pancreatic anastomotic leak | 5 (18) |
| Clostridium difficile colitis | 2 (7) |
| Urinary tract infection | 2 (7) |
| Parotiditis | 1 (4) |
| Survival, n (%) | |
| Short-term survival (< 5 years) | 17 (63) |
| Long-term survival (> 5 years) | 3 (11) |
| Lost to follow up | 7 (26) |
Continuous data presented as mean ± standard deviation. BMI Body mass index, SSI Surgical site infection